



PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/735,461-Conf. #3119
Filing Date	December 11, 2003
First Named Inventor	Michael P. CZECH
Art Unit	1635
Examiner Name	R. A. Schnizer
Attorney Docket Number	UMY-055

ENCLOSURES (Check all that apply)

- | | | |
|---|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to TC |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Terminal Disclaimer | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Request for Refund | Return Receipt Postcard |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> CD, Number of CD(s) _____ | PTO form SB/08 |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> Landscape Table on CD | Certificate of Mailing |
| <input type="checkbox"/> Reply to Missing Parts/Incomplete Application | | Copies of Seventeen (17) References |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | | |

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	LAHIVE & COCKFIELD LLP		
Signature			
Printed name	Debra J. Milasincic, Esq.		
Date	July 9, 2007	Reg. No.	46,931

Express Mail Label No. EV 956462079 US Dated: July 9, 2007



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL For FY 2007

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	10/735,461-Conf. #3119
Filing Date	December 11, 2003
First Named Inventor	Michael P. CZECH
Examiner Name	R. A. Schnizer
Art Unit	1635
Attorney Docket No.	UMY-055

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 12-0080 Deposit Account Name: Lahive & Cockfield, LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims Extra Claims Fee (\$)

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims Extra Claims Fee (\$)

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$)

4. OTHER FEE(S)

Non-English Specification. \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	46,931
Name (Print/Type)	Debra J. Milasincic, Esq.	Telephone	(617) 227-7400
		Date	July 9, 2007



07-10-07

DFW #

Express Mail Label No. EV 956462079 US Dated: July 9, 2007

Docket No.: UMY-055
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michael P. Czech *et al.*

Application No.: 10/735,461

Confirmation No.: 3119

Filed: December 11, 2003

Art Unit: 1635

For: METHOD OF INTRODUCING siRNA INTO
ADIPOCYTES

Examiner: R. A. Schnizer

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have not submitted a copy of the cited U.S. patent application in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

07/10/2007 TNGUYEN2 00000034 120080 10735461

01 FC:1806 180.00 DA


This Information Disclosure Statement is filed after the mailing date of a Final Office Action but before payment of the Issue Fee (37 CFR 1.97(d)). Applicants hereby petition that the Information Disclosure Statement be considered.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. UMY-055.

Dated: July 9, 2007

DJM/MBC/mch

Respectfully submitted,

By 
Debra J. Milasincic, Esq.
Registration No.: 46,931
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant



Application No. (if known): 10/735,461


Attorney Docket No.: UMY-055

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 956462079 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 9, 2007
Date



Signature

Debra J. Milasincic, Esq.

Typed or printed name of person signing Certificate

46,931

Registration Number, if applicable

(617) 227-7400

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard
Transmittal (1 page)
Fee Transmittal (1 page, in duplicate)
Supplemental Information Disclosure Statement (2 pages)
PTO form SB/08 (18 References) (2 pages)
Copies of Seventeen (17) References



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/735,461-Conf. #3119
				Filing Date	December 11, 2003
				First Named Inventor	Michael P. CZECH
				Art Unit	1635
				Examiner Name	R. A. Schnizer
Sheet	1	of	2	Attorney Docket Number	UMY-055

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-20020162126-A1	10-31-2002	Beach et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-99/32619-A1	07-01-1999	The Carnegie Institute of Washington et al		
	B2	WO-99/54465-A2	10-28-1999	Warner-Lambert Company et al.		
	B3	WO-00/31291-A1	06-02-2000	Pharmacia & Upjohn AB		
	B4	WO-01/75164-A2	10-11-2001	Whitehead Institute for Biomedical Research et al		
	B5	WO-01/93669-A2	12-13-2001	Devgen NV		
	B6	WO-02/33046-A2	04-25-2002	University of Massachusetts		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Bose, Avirup et al., "Gα11 Signaling through ARF6 Regulates F-Actin Mobilization and GLUT4 Glucose Transporter Translocation to the Plasma Membrane," <i>Molecular and Cellular Biology</i> , Vol. 21(15):5262-5275 (2001)	
	C2	Bose, Avirup et al., "Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c," <i>Nature</i> , Vol. 420(6917):821-824 (2002)	
	C3	Czaderna, Frank et al., "Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA," <i>Nucleic Acids Research</i> , Vol. 31(2):670-682 (2003)	
	C4	Elbashir, Sayda M. et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , Vol. 26:199-213 (2002)	
	C5	Izuishi, Kunihiko et al., "Remarkable Tolerance of Tumor Cells to Nutrient Deprivations: Possible New Biochemical Target for Cancer Therapy," <i>Cancer Research</i> , Vol. 60:6201-6207 (2000)	
	C6	Min, Jing et al., "Synip: A Novel Insulin-Regulated Syntaxin 4-Binding Protein Mediating GLUT4 Translocation in Adipocytes," <i>Molecular Cell</i> , Vol. 3:751-760 (1999)	
	C7	Paradis, Suzanne et al., "Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor," <i>Genes & Development</i> , Vol. 12:2488-2498 (1998)	
	C8	Siegmund, Daniela et al., "Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis," <i>Molecular Medicine</i> , Vol. 8(11):725-732 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/735,461-Conf. #3119
				Filing Date	December 11, 2003
				First Named Inventor	Michael P. CZECH
				Art Unit	1635
				Examiner Name	R. A. Schnizer
Sheet	2	of	2	Attorney Docket Number	UMY-055

	C9	Tuschl, Thomas et al., "Small Interfering RNAs: A Revolutionary Tool for the analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , Vol. 2(3):158-167 (2002)	
	C10	Walters, D.K. et al., "The Effectiveness of Double-Stranded Short Inhibitory RNAs (siRNAs) May Depend on the Method of Transfection," <i>Antisense and Nucleic Acid Drug Development</i> , Vol. 12:411-418 (2002)	
	C11	Weil, D. et al., "Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells," <i>BioTechniques</i> , Vol. 33(6):1244-1248 (2002)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--